UPDATE: Eli Lilly Says Galcanezumab Showed 'statistically significant reduction in the number of monthly migraine headache days with both doses (5.6 days for 120 mg and 6.5 days for 240 mg, p<0.001 for both dosing groups)'
Paul Quintaro